akt1-e17k

Miransertib (ARQ-092) 是一种具有口服活性的，选择性和变构性Akt 抑制剂。它有效抑制利什曼原虫，还是 AKT1-E17K 突变蛋白抑制剂，可研究PI3K AKT 驱动的肿瘤和 Proteus 综合征。

Afuresertib hydrochloride 是一个口服有效的，ATP 竞争性的选择性泛Akt 抑制剂，作用于Akt1、Akt2和Akt3，Ki 值分别为 0.08、2和 2.6 nM。

Miransertib hydrochloride (ARQ-092 hydrochloride) is a powerful, orally bioavailable, selective, and allosteric inhibitor of Akt. It exhibits an inhibitory concentration (IC50) of 2.7 nM, 14 nM, and 8.1 nM against Akt1, Akt2, and Akt3, respectively. In addition to its Akt inhibitory activity, Miransertib hydrochloride also demonstrates significant potency as an inhibitor of the AKT1-E17K mutant protein. This compound shows promise in research related to PI3K AKT-driven tumors and Proteus syndrome. Furthermore, Miransertib hydrochloride displays efficacy against Leishmania [1, 2].

Vevorisertib trihydrochloride(ARQ 751 trihydrochloride) 是一种具有选择性和有效性的 pan-AKT 和 AKT1-E17K 突变抑制剂，抑制 AKT1 、AKT2 和 AKT3 。 Vevorisertib trihydrochloride 可用于研究肝癌和晚期实体瘤。

Akt1-IN-3 (Compd 7) 为专门针对 AKT1 的抑制剂，对 AKT1-E17K 有高效的抑制作用，IC50 值低于 15 nM。

Akt1-IN-4 (Compound 62) 作为一种高效的AKT1-E17K抑制剂，其IC50值低于 15 nM。